We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Illumina (ILMN - Free Report) to post quarterly earnings of $1.05 per share in its upcoming report, which indicates a year-over-year increase of 8.3%. Revenues are expected to be $1.08 billion, up 3.6% from the year-ago quarter.
The current level reflects an upward revision of 1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Illumina metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenue- Product revenue- Consumable' will reach $790.02 million. The estimate suggests a change of +2.9% year over year.
The consensus among analysts is that 'Revenue- Service and other revenue' will reach $166.59 million. The estimate indicates a year-over-year change of +3.5%.
The average prediction of analysts places 'Revenue- Sequencing- Consumables' at $713.41 million. The estimate indicates a year-over-year change of +2.5%.
According to the collective judgment of analysts, 'Revenue- Sequencing- Instruments' should come in at $108.78 million. The estimate suggests a change of -0.2% year over year.
Analysts expect 'Revenue- Product revenue- Instruments' to come in at $110.73 million. The estimate indicates a year-over-year change of -1.1%.
The combined assessment of analysts suggests that 'Revenue- Product revenue' will likely reach $900.42 million. The estimate indicates a year-over-year change of +2.3%.
The consensus estimate for 'Revenue- Microarrays- Instruments' stands at $2.92 million. The estimate indicates a year-over-year change of -2.7%.
Analysts forecast 'Revenue- Microarrays- Consumables' to reach $77.43 million. The estimate indicates a change of +7.5% from the prior-year quarter.
Over the past month, Illumina shares have recorded returns of +3% versus the Zacks S&P 500 composite's +12.2% change. Based on its Zacks Rank #3 (Hold), ILMN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts expect Illumina (ILMN - Free Report) to post quarterly earnings of $1.05 per share in its upcoming report, which indicates a year-over-year increase of 8.3%. Revenues are expected to be $1.08 billion, up 3.6% from the year-ago quarter.
The current level reflects an upward revision of 1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Illumina metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenue- Product revenue- Consumable' will reach $790.02 million. The estimate suggests a change of +2.9% year over year.
The consensus among analysts is that 'Revenue- Service and other revenue' will reach $166.59 million. The estimate indicates a year-over-year change of +3.5%.
The average prediction of analysts places 'Revenue- Sequencing- Consumables' at $713.41 million. The estimate indicates a year-over-year change of +2.5%.
According to the collective judgment of analysts, 'Revenue- Sequencing- Instruments' should come in at $108.78 million. The estimate suggests a change of -0.2% year over year.
Analysts expect 'Revenue- Product revenue- Instruments' to come in at $110.73 million. The estimate indicates a year-over-year change of -1.1%.
The combined assessment of analysts suggests that 'Revenue- Product revenue' will likely reach $900.42 million. The estimate indicates a year-over-year change of +2.3%.
The consensus estimate for 'Revenue- Microarrays- Instruments' stands at $2.92 million. The estimate indicates a year-over-year change of -2.7%.
Analysts forecast 'Revenue- Microarrays- Consumables' to reach $77.43 million. The estimate indicates a change of +7.5% from the prior-year quarter.
View all Key Company Metrics for Illumina here>>>Over the past month, Illumina shares have recorded returns of +3% versus the Zacks S&P 500 composite's +12.2% change. Based on its Zacks Rank #3 (Hold), ILMN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .